Latest News
RESCUE’S Most Recent Findings from Systemic Review Published in The Lancet
RESCEU scientists publish their most recent paper in The Lancet, focusing on the global disease burden of and risk factors for acute lower respiratory infections caused by respiratory syncytial virus in preterm infants and young children. Top 3 Findings (Infographic) in PDF format Access the full publication here.
RESCEU’s RSV Global Disease Burden study reveals substantial RSV community morbidity and mortality burden in young children in low- and middle-income countries
RESCEU scientists publish latest global disease burden estimates of RSV in The Lancet revealing substantial RSV community morbidity and mortality burden in young children in low- and middle-income countries (LMICs). Some of the most relevant findings are: Globally, 33 million episodes of RSV acute lower respiratory infection (including pneumonia and bronchiolitis) occur annually, with 95% …
RSV Patient Advisory Board publishes paper about patient involvement in RSV Research
RSV is a major cause of morbidity and mortality among young children, and also causes a substantial disease burden among elderly and high-risk adults. Involving patients in scientific research on RSV is of great importance to improve its quality and relevance. The RSV Patient Advisory Board (PAB) has drawn attention for more patient participation in …
BronchStart study will help predict RSV epidemics
Non-pharmaceutical interventions to slow or eliminate the spread of COVID-19 have had dramatic consequences on the transmission of other respiratory viruses, in particular Respiratory Syncytial Virus (RSV) in children. Now, the BronchStart surveillance study funded by RESCEU, will contribute to identify and interpret the impact of delayed bronchiolitis epidemic in the UK and Ireland. The …
Continue reading "BronchStart study will help predict RSV epidemics"
RSV care in Europe versus low- and middle-income countries
Respiratory syncytial virus (RSV) is the most common cause of acute lower respiratory tract infections (bronchiolitis and pneumonia) in infants and young children worldwide.[1,2] RSV is also the leading cause of hospitalisations in infants.[3] RSV accounts for up to 80% of all hospitalisations for bronchiolitis in infants younger than 1 year at the peak of …
Continue reading "RSV care in Europe versus low- and middle-income countries"
Europe’s project RESCEU sheds new light on the fight against the Respiratory Syncytial Virus and its economic impact
RESCEU scientists publish supplement in Journal of Infectious Diseases revealing impact of RSV, the most common cause of severe respiratory illness in infants and children worldwide. • Globally, an estimated 33 million young children are diagnosed with RSV each year, over 3 million cases require hospitalisation. Annually, the virus causes 118,000 deaths. • RSV costs …
The Patient Advisory Board takes a great leap forward in raising awareness about RSV
A key aspect to prevent the infection caused by RSV (Respiratory Syncytial Virus) and its sequels amongst young babies is making parents more aware of its existence. This last year, RESCEU’s Patient Advisory Board (PAB) has made a great leap forward by designing and implementing a plan aimed at promoting awareness about this common and …
ISAG encourages RESCEU to export its framework to fight vaccine preventable diseases such as COVID-19
The International Scientific Advisory Group (ISAGs) played a primary role, at RESCEU 4th GAM. Precisely, one of the main responsibilities of this body of experts on scientific and technical matters relevant to the project is to provide advice to the General Assembly and the Steering Committee and support their decision making. In this year’s General Assembly …
Early career researchers take the floor at RESCEU’s virtual 4th GAM
RSV research has a bright future judging by the good work and implication shown by the early career researchers during RESCEU’s virtual 4th General Assembly Meeting (GAM). Indeed, this year’s edition wanted to bring into focus the contribution young scientists are making to the project which intends to build knowledge on RSV for the future development …
Continue reading "Early career researchers take the floor at RESCEU’s virtual 4th GAM"
RESCEU’s GAM goes virtual to continue fostering scientific debate around RSV
RESCEU celebrated its 4th General Assembly Meeting last 17th and 18th of June in exceptional circumstances due to COVID-19. The plans to congregate RESCEU’s Consortium members in the historical city of Edinburg to celebrate the 4th General Assembly Meeting (GAM) in a three-day event were cut short by COVID-19. Given this year’s challenging circumstances, knowledge sharing, and scientific …
Continue reading "RESCEU’s GAM goes virtual to continue fostering scientific debate around RSV"
Get to Know the RESCEU Team! This month we talk to Joanne Wildenbeest from UMCU
Joanne Wildenbeest is a paediatric infectious diseases specialist at the Wilhelmina Children’s Hospital, University Medical Center Utrecht. Tell us about your professional career. I am a paediatric infectious diseases specialist and researcher at the Wilhelmina Children’s Hospital, University Medical Center Utrecht. I studied medicine at Ghent University in Belgium. After graduating I started my …
Continue reading "Get to Know the RESCEU Team! This month we talk to Joanne Wildenbeest from UMCU"
RESCEU Mid-Term Review
In February, IMI organised the Mid-Term Review of our project that took place in Brussels. A team of 20 people represented our consortium in front of our Project Officer, Isabella Tamagnini, and three reviewers: Dimitrios Athanasious, Dirk Jochmans and Tanel Tenson. During the meeting, a representative of each work package exposed their achievements and explained …
Get to Know the RESCEU Team! This month we talk to Nicolas Voirin from SP
Nicolas Voirin is founder and managing member of EPIMOD, a company providing applied research services in epidemiology and modeling of infectious diseases. As a scientist, his main interest is understanding infectious diseases epidemiology, prevention, treatment and control through statistical and mathematical modelling. Tell us about your professional career. I received training in biology, …
Continue reading "Get to Know the RESCEU Team! This month we talk to Nicolas Voirin from SP"
Prevention of Severe RSV in Infants: ongoing studies and vaccine strategies
Harish Nair, University of Edinburgh (UK), RESCEU Project Coordinator, and Louis J. Bont, University Medical Center Utrecht (NL), RESCEU Work Package Leader, have recently taken part in an Experts Panel Discussion on RSV, hosted by the platform Peervoice and endorsed by ReSViNET. Together with Asuncion Mejias, from the Nationwide Children’s Hospital, Columbus, Ohio (USA), they …
Continue reading "Prevention of Severe RSV in Infants: ongoing studies and vaccine strategies"
RESCEU presented at the EMA Vaccine Working Party Meeting
RESCEU Work Package 2 representatives met with the EMA Vaccine Working Party (VWP) on June 7th at the EMA in London, as part of the RESCEU efforts for establishing continuous communication and collaboration with Regulatory Bodies. The meeting began with a presentation of RESCEU, including an overview of the project and a detailed explanation of …
Continue reading "RESCEU presented at the EMA Vaccine Working Party Meeting"
EMA ITF Briefing Meeting with RESCEU representatives held in London
An EMA ITF Briefing Meeting with RESCEU representatives took place on March 16th at the EMA headquarters, as part of the RESCEU efforts for establishing continuous communication and collaboration with Regulatory Bodies. The purpose of this collaboration is to allow RESCEU to receive fundamental regulatory input but also provide, thanks to its experts and the data …
Continue reading "EMA ITF Briefing Meeting with RESCEU representatives held in London"
First RESCEU’s Clinical Studies patients tested
RESCEU’s clinical studies have started, with the aim of gathering data and addressing knowledge gaps on the impact of RSV infections. The investigation is building on the knowledge of a varied team of partners from universities and public health institutions, and includes 3 cohort studies on vulnerable populations (infants, older adults, COPD subjects) and one …
Continue reading "First RESCEU’s Clinical Studies patients tested"
RESCEU becomes ISARIC member
We are glad to announce the RESCEU membership in the International Severe Acute Respiratory and Emerging Infection Consortium (ISARIC). It is a global initiative aiming to ensure that clinical researchers have the open access protocols and data-sharing processes needed to facilitate a rapid response to emerging diseases that may turn into epidemics or pandemics. Please follow …
Kick off meeting
After many months of intensive preparatory work following a competitive call process, the Respiratory Syncytial Virus Consortium in Europe (RESCEU) was launched in January 2017. The RESCEU project aims to develop robust evidence on RSV disease burden and economic impact; create a sustainable Europe-wide multidisciplinary, multi-stakeholder community from academia, public health, scientific societies, patient organisations, …
€29m research grant to assess risk posed by deadly lung infections
Experts have received €29 million (£24m) to investigate serious lung infections that particularly affect babies and older people. Diseases caused by respiratory syncytial virus (RSV) are estimated to affect more than 30 million children under five each year throughout the world. The virus also affects older people and those with weakened immune systems, including cancer …
Continue reading "€29m research grant to assess risk posed by deadly lung infections"